How to cite item

Radioimmunotherapy in limited-stage diffuse large B-cell lymphoma

   
@article{TCR6468,
	author = {Yi Miao and Lei Fan and Jianyong Li},
	title = {Radioimmunotherapy in limited-stage diffuse large B-cell lymphoma},
	journal = {Translational Cancer Research},
	volume = {5},
	number = {1},
	year = {2016},
	keywords = {},
	abstract = {Patients with limited-stage aggressive B-cell lymphoma without adverse risk factors are generally cured when treated by short-term therapy, with overall survival (OS) at 10 years ranging from 94% to 97% (1,2). However, limited-stage diffuse large B-cell lymphoma (DLBCL) patients with adverse risk factors including stage II disease, age >60 years, elevated serum lactate dehydrogenase (LDH), and poor performance status have a relatively unfavorable outcome, with a 5-year OS of 50% to 77% and a 10-year OS of 0% to 50%, and treatment optimization is needed for this subtype patients (1-4).},
	issn = {2219-6803},	url = {https://tcr.amegroups.org/article/view/6468}
}